Skip to main content

Loading market data...

ACAD

Acadia Pharmaceuticals Inc.

NASDAQ • United states

$19.80

+$0.68

(+3.56%)

Source: Yahoo Finance · Quote time Oct 19, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Acadia Pharmaceuticals Inc. (ACAD)

Unavailable

Quotes may be delayed

$3.41B

Market Cap

1,298,611

Volume

9.0

P/E Ratio

Unavailable

Div Yield

Acadia Pharmaceuticals Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 12830 EL CAMINO REAL, SAN DIEGO, CA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

24 Sep 2026

ACADIA Pharmaceuticals Inc. reported Regulation FD disclosure

ACADIA Pharmaceuticals Inc. filed an 8-K covering Regulation FD disclosure, another company event, supporting financial statements or exhibits.

11 Sep 2026

ACADIA Pharmaceuticals Inc. reported Another company event

ACADIA Pharmaceuticals Inc. filed an 8-K covering another company event, supporting financial statements or exhibits.

7 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in ACADIA Pharmaceuticals Inc..

4 Aug 2026

ACADIA Pharmaceuticals Inc. filed Form 10-Q

ACADIA Pharmaceuticals Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

4 Aug 2026

ACADIA Pharmaceuticals Inc. reported Operating or financial results

ACADIA Pharmaceuticals Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$384.99M

Total assets (USD)$1.74B

Total liabilities (USD)$436.29M

Shareholders' equity (USD)$1.31B

Debt due within a year (USD)$22,000

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$307.96M	$37.84M	$31.50M	$0.18	10-Q · 5 Aug 2026
Q1 2026	$268.06M	−$4.62M	$3.64M	$0.02	10-Q · 7 May 2026
Q4 2025	$283.99M	$17.39M	$273.57M	Unavailable	10-K · 26 Feb 2026
Q3 2025	$278.63M	$35.76M	$71.78M	$0.42	10-Q · 6 Nov 2025
Q2 2025	$264.57M	$32.37M	$26.67M	$0.16	10-Q · 7 Aug 2025
Q1 2025	$244.32M	$19.29M	$18.99M	$0.11	10-Q · 8 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $31.43

58.7% upside potential

📈

Strong Buy

Unavailable

👍

Buy

10

⏸️

Hold

4

📉

Sell

0

14 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 20 Oct 2026, 10:49 UTC Targets range 23.00–37.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

6

Aug 2026

Schneyer Mark C.

EVP, CHIEF FINANCIAL OFFICER

Option exercise

$17.84 per share

14,292 shares

6

Aug 2026

Schneyer Mark C.

EVP, CHIEF FINANCIAL OFFICER

Open-market sale

$29.22 per share

14,292 shares

5

Aug 2026

Schneyer Mark C.

EVP, CHIEF FINANCIAL OFFICER

Option exercise

$17.84 per share

5,849 shares

5

Aug 2026

Schneyer Mark C.

EVP, CHIEF FINANCIAL OFFICER

Open-market sale

$29.00 per share

5,849 shares

30

Jul 2026

Thompson Elizabeth H.Z.

EVP, Head of Research & Dev

Open-market sale

$26.13 per share

16,558 shares

29

Jul 2026

Thompson Elizabeth H.Z.

EVP, Head of Research & Dev

Option exercise

Unavailable per share

32,272 shares

26

Jun 2026

Kihara James

PRINCIPAL ACCOUNTING OFFICER

Open-market sale

$26.08 per share

11,421 shares

29

May 2026

BAKER BROS. ADVISORS LP

Director

Grant or award

Unavailable per share

37,244 shares

29

May 2026

HARRIGAN EDMUND

Director

Option exercise

Unavailable per share

8,107 shares

29

May 2026

Ndu Adora

Director

Option exercise

Unavailable per share

8,107 shares

Top Shareholders

Baker Bros. Advisors Lp

42,912,904 shares

0.038% change

6/30/2026

Blackrock, Inc.

22,515,173 shares

4.474% change

6/30/2026

Vanguard Group Inc

15,153,957 shares

-0.167% change

12/31/2025

State Street Corp

9,076,212 shares

8.922% change

6/30/2026

Vanguard Portfolio Management Llc

8,838,450 shares

1.924% change

6/30/2026

Rtw Investments, Lp

7,144,524 shares

0% change

6/30/2026

Vanguard Capital Management Llc

5,763,750 shares

1.808% change

6/30/2026

Dimensional Fund Advisors Lp

3,694,988 shares

17.109% change

6/30/2026

Geode Capital Management, Llc

3,358,129 shares

-3.076% change

6/30/2026

Palo Alto Investors Lp

2,864,096 shares

-0.299% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 20 Oct 2026, 10:49 UTC· 2 days ago

Research coverage and investment tools

Acadia Pharmaceuticals Inc. (ACAD) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$19.80 on 19 Oct 2026. That is 11% of the way from its 52-week low of US$18.39 to its 52-week high of US$30.96. Its market capitalisation was US$3.41 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$307.96M	$37.84M	$31.50M	$0.18	—	12.3%	$95.69M	10-Q · 5 Aug 2026 (opens in a new tab)
Q1 2026	$268.06M	−$4.62M	$3.64M	$0.02	—	-1.7%	$28.77M	10-Q · 7 May 2026 (opens in a new tab)
Q4 2025	$283.99M	$17.39M	$273.57M	Unavailable	—	6.1%	−$52.74M	10-K · 26 Feb 2026 (opens in a new tab)
Q3 2025	$278.63M	$35.76M	$71.78M	$0.42	—	12.8%	$73.90M	10-Q · 6 Nov 2025 (opens in a new tab)
Q2 2025	$264.57M	$32.37M	$26.67M	$0.16	—	12.2%	$63.66M	10-Q · 7 Aug 2025 (opens in a new tab)
Q1 2025	$244.32M	$19.29M	$18.99M	$0.11	—	7.9%	$20.32M	10-Q · 8 May 2025 (opens in a new tab)

Cash and equivalents: $384.99M
Total assets: $1.74B
Total liabilities: $436.29M
Shareholders' equity: $1.31B
Debt due within a year: $22,000

8-K · 24 Sep 2026

ACADIA Pharmaceuticals Inc. reported Regulation FD disclosure (opens in a new tab)

ACADIA Pharmaceuticals Inc. filed an 8-K covering Regulation FD disclosure, another company event, supporting financial statements or exhibits.
8-K · 11 Sep 2026

ACADIA Pharmaceuticals Inc. reported Another company event (opens in a new tab)

ACADIA Pharmaceuticals Inc. filed an 8-K covering another company event, supporting financial statements or exhibits.
SCHEDULE 13G · 7 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in ACADIA Pharmaceuticals Inc..
10-Q · 4 Aug 2026

ACADIA Pharmaceuticals Inc. filed Form 10-Q (opens in a new tab)

ACADIA Pharmaceuticals Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 4 Aug 2026

ACADIA Pharmaceuticals Inc. reported Operating or financial results (opens in a new tab)

ACADIA Pharmaceuticals Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

Insider	Date	Transaction	Shares	Average price	Filing
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER	6 Aug 2026	Option exercise (M)	+14,292	$17.84	Form 4 (opens in a new tab)
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER	6 Aug 2026	Open-market sale (S)	−14,292	$29.22	Form 4 (opens in a new tab)
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER	5 Aug 2026	Option exercise (M)	+5,849	$17.84	Form 4 (opens in a new tab)
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER	5 Aug 2026	Open-market sale (S)	−5,849	$29.00	Form 4 (opens in a new tab)
Thompson Elizabeth H.Z. EVP, Head of Research & Dev	30 Jul 2026	Open-market sale (S)	−16,558	$26.13	Form 4 (opens in a new tab)
Thompson Elizabeth H.Z. EVP, Head of Research & Dev	29 Jul 2026	Option exercise (M)	+32,272	—	Form 4 (opens in a new tab)
Kihara James PRINCIPAL ACCOUNTING OFFICER	26 Jun 2026	Open-market sale (S)	−11,421	$26.08	Form 4 (opens in a new tab)
BAKER BROS. ADVISORS LP Director	29 May 2026	Grant or award (A)	+37,244	—	Form 4 (opens in a new tab)
HARRIGAN EDMUND Director	29 May 2026	Option exercise (M)	+8,107	—	Form 4 (opens in a new tab)
Ndu Adora Director	29 May 2026	Option exercise (M)	+8,107	—	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Baker Bros. Advisors Lp	6/30/2026	42,912,904	0.038%
Blackrock, Inc.	6/30/2026	22,515,173	4.474%
Vanguard Group Inc	12/31/2025	15,153,957	-0.167%
State Street Corp	6/30/2026	9,076,212	8.922%
Vanguard Portfolio Management Llc	6/30/2026	8,838,450	1.924%
Rtw Investments, Lp	6/30/2026	7,144,524	0%
Vanguard Capital Management Llc	6/30/2026	5,763,750	1.808%
Dimensional Fund Advisors Lp	6/30/2026	3,694,988	17.109%
Geode Capital Management, Llc	6/30/2026	3,358,129	-3.076%
Palo Alto Investors Lp	6/30/2026	2,864,096	-0.299%

Previous close: 19.12 USD
Day range: 19.11 – 19.84 USD
52-week range: 18.39 – 30.96 USD
Volume: 1,298,611
Market cap: $3.41B
Average volume: 1,833,225
P/E ratio: 9.0
EPS (FY 2025, diluted): 2.30 USD
Shares outstanding: 172.31M
Beta (5Y monthly): 0.89

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 19 Oct 2026, 20:00 UTC· 2 days ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 08:08 UTC· 3 hours ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for ACAD yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.